» Articles » PMID: 35980263

Role of Radiosurgery in the Treatment of Cushing's Disease

Overview
Specialty Endocrinology
Date 2022 Aug 18
PMID 35980263
Authors
Affiliations
Soon will be listed here.
Abstract

Radiotherapy is a useful adjuvant treatment for patients with Cushing's disease that is not cured by surgery. In particular, Gamma Knife radiosurgery (GKRS) has been increasingly used worldwide as the preferred radiation technique in patients with persistent or recurrent Cushing's disease. The most widely accepted criterion for hormonal remission after GKRS is normalization of urinary free cortisol (UFC) levels. When a clear biological target is not identified, irradiation of the whole pituitary gland can be considered. The 5-year probability of remission is 65%-75%. Normalization of hypercortisolism usually occurs within 3 years from GKRS treatment and control of tumor growth is optimal, approaching more than 90%. No clear predictor of a favorable outcome has emerged up to now, except for the experience of the treating team. In the largest series, development of partial or complete hypopituitarism occurred between 15% and 36%. Severe side effects of GKRS, such as optic neuropathy and oculomotor palsy, are uncommon but have been documented in patients previously exposed to radiation. Recurrence of disease has been reported in as high as 16%-18% of the patients who achieved normalization of UFC levels in the two largest series, whereas smaller series did not describe late failure of GKRS. The reason for this discrepancy is unclear, as is the relationship between hormonal and tumoral recurrence. Another unresolved issue is whether treatment with adrenal blocking drugs can jeopardize the results of GKRS. GKRS is an effective second-line treatment in patients with Cushing's disease not cured by surgery. Hypopituitarism is the most frequent side effect of GKRS, whereas severe neurologic complications are uncommon in radiation-naïve patients.

Citing Articles

Distinguishing Cushing's disease from the ectopic ACTH syndrome: Needles in a haystack or hiding in plain sight?.

Hayes A, Grossman A J Neuroendocrinol. 2022; 34(8):e13137.

PMID: 35980277 PMC: 9542389. DOI: 10.1111/jne.13137.


Long-term effects of glucocorticoid excess on the brain.

Dekkers A, Amaya J, van der Meulen M, Biermasz N, Meijer O, Pereira A J Neuroendocrinol. 2022; 34(8):e13142.

PMID: 35980208 PMC: 9541651. DOI: 10.1111/jne.13142.


Aggressive corticotroph tumors and carcinomas.

Lasolle H, Vasiljevic A, Jouanneau E, Ilie M, Raverot G J Neuroendocrinol. 2022; 34(8):e13169.

PMID: 35979732 PMC: 9542524. DOI: 10.1111/jne.13169.


Cardiovascular complications of Cushings syndrome: Impact on morbidity and mortality.

Clayton R J Neuroendocrinol. 2022; 34(8):e13175.

PMID: 35764311 PMC: 9541180. DOI: 10.1111/jne.13175.


The diagnosis and management of Cushing's syndrome in pregnancy.

Hamblin R, Coulden A, Fountas A, Karavitaki N J Neuroendocrinol. 2022; 34(8):e13118.

PMID: 35491087 PMC: 9541401. DOI: 10.1111/jne.13118.